J Korean Diabetes > Volume 16(4); 2015 > Article
The Journal of Korean Diabetes 2015;16(4):310-314.
DOI: https://doi.org/10.4093/jkd.2015.16.4.310    Published online December 24, 2015.
Sodium-Glucose Cotransporter 2 억제제 사용 후 발생한 케톤산증 1예
전제혁, 최경진, 우영민, 박예림, 박윤규, 김원준, 심명숙, 김진엽
A Case of Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter 2 Inhibitor.
Jae Hyuck Jun, Kyung Jin Choe, Yeong Min Woo, Ye Rim Park, Yoon Kyoo Park, Won Jun Kim, Myoung Sook Shim, Jin Yeob Kim
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. kozmozman@gnah.co.kr
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral antihyperglycemic drugs; inhibition of the cotransporter allows for increased renal glucose excretion that consequently leads to reduced plasma glucose level. We report a rare case of a 73-year-old woman with type 2 diabetes mellitus who developed severe ketoacidosis caused by an SGLT2 inhibitor. At admission, severe ketoacidosis with arterial PH 6.99 was observed, though her serum glucose level of 232 mg/dL was not excessively high. It is necessary to pay attention to patients with type 2 diabetes being treated with an SGLT2 inhibitor, as anorexia, diarrhea, dehydration, and weight loss can develop in conjunction with a high fat/protein diet.
Key Words: Diabetes mellitus, Ketosis, Sodium-glucose cotransporter 2

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer